The Beat

In this episode, host Sandy Vance and Hari Balasubramanian, the Chief Technology Officer, Health Information Systems at Solventum, sit down for a deep dive into how AI-driven healthcare technology is reshaping the industry. Together, they explore how Solventum is building innovative products and services that streamline documentation, billing, and coding while improving the patient experience and saving valuable time for healthcare professionals. From what’s happening at Solventum right now to the company’s move toward fully autonomous coding, this conversation unpacks how healthcare payers and providers can rethink financial performance in the age of artificial intelligence. Hari also shares practical insights for CIOs evaluating these systems and explains how Solventum measures real-world improvements driven by AI. If you’re interested in healthcare innovation, revenue cycle transformation, or the future of AI in health information systems, this is an episode you won’t want to miss.Check out Solventum’s Education Session and Case Study Session that was presented in the AI Zone at HLTH 2025.In this episode, they talk about:What’s going on with Solventum right nowHow Solventum is serving healthcare payersSolventum’s move toward complete autonomous codingThe common misconceptions about improving financial performance for providersHow CIOs should evaluate their work when engaging with these systemsMeasuring the improvements produced by AI with Solventum’s systemsA Little About Hari:Hari Bala joined Solventum as Chief Technology Officer, Health Information Systems, in May 2025, bringing more than 25 years of experience building large-scale, distributed systems across healthcare, cloud, and security, with deep expertise in GenAI, data science, analytics, and machine learning. Previously, he led AI, data, analytics, and cloud transformation efforts at GE Healthcare and Oracle Cerner, where he helped establish Oracle’s AI Services organization and later led the Health Data Intelligence and Analytics platform following the Cerner acquisition. Earlier, Hari spent nearly 19 years at Microsoft in leadership roles spanning Azure, Search, Cosmos DB, Windows, Office 365, and mobile and browser technologies.

About Bari Kowal:Bari Kowal is a senior biopharmaceutical executive with over 30 years of experience leading global operations, clinical development, and strategic portfolio management. As Senior Vice President at Regeneron, she oversees development operations, enterprise-wide portfolio strategy, risk management, and major technology initiatives, helping guide the company’s continued growth and innovation. Her career spans leadership roles at Pfizer, ICON Clinical Research, Valera Pharmaceuticals, PDL BioPharma, GenVec, and Covance, where she built high-performing teams and drove operational excellence across clinical operations and strategic programs. Bari also serves on the Board of Directors of TransCelerate BioPharma Inc., contributing to industry-wide efforts to streamline and strengthen clinical trial execution. She is known for her governance expertise, collaborative leadership style, and ability to deliver organizational transformation at scale. Bari holds a master’s degree in neuroscience from New York University, with additional academic training from the University of Pennsylvania and Binghamton University.Things You’ll Learn:Expanding access to clinical trials requires educating both patients and physicians, many of whom are unfamiliar with how to engage in research. Better awareness can dramatically increase participation and diversify trial populations.Technology alone will not speed up drug development unless systems are connected end-to-end. Interoperability is the real catalyst for reducing inefficiencies across discovery, development, and regulatory submission.Clean, structured data is the foundation of meaningful AI adoption in healthcare. Without it, predictive models and trial optimization tools cannot reach their potential.Trial complexity is one of the most significant barriers to faster development timelines. Streamlining procedures, reducing unnecessary tests, and learning from regulatory feedback can significantly accelerate progress.Sustainable clinical research requires equipping trial sites with greater capacity and support. Even when the right patients are identified, sites must be capable of enrolling and managing them effectively.Resources:Connect with and follow Bari Kowal on LinkedIn.Follow Regeneron on LinkedIn and visit their website.

About Madhu Pawar:Madhu Pawar is a board director and cross-disciplinary technology leader operating at the intersection of healthcare, data, and product innovation. She serves on the Board of Directors at Talkspace (NASDAQ: TALK) and is the Chief Product Officer for Optum Insight, where she drives product strategy and platform innovation across UnitedHealth Group’s most critical assets. Prior to Optum, she spent over six years at Google leading the global SMB Ads product ecosystem—overseeing AI-driven insights platforms, multi-billion-dollar revenue lines, and large-scale engineering, product, and operations teams across multiple continents. Madhu also teaches consumer analytics in healthcare as an adjunct professor at Carnegie Mellon University. Earlier in her career, she was a partner in McKinsey’s Global Healthcare Practice, where she built and scaled technology and services businesses for payers, providers, and fast-growth health companies. She began her career in software engineering at Hewlett-Packard Labs, earning patents in authentication and location-aware computing, followed by roles at PwC in security and technology. Madhu holds graduate degrees from Stanford School of Medicine and Carnegie Mellon University and a bachelor’s in computer engineering from Nanyang Technological University.Things You’ll Learn:Real-time data exchange between payers and providers can significantly reduce the confusion, delays, and costs associated with today’s claims processes. AI-enabled reasoning over contracts and encounters improves accuracy from the start.Optum Real aims to bridge the transparency gap by connecting stakeholders through a multi-party hub, enabling real-time understanding of coverage and reimbursement. Early pilots show tangible reductions in denials and improved patient clarity.The majority of first-time denied claims are avoidable, signaling an industry-wide opportunity to remove unnecessary rework. Solving this problem increases efficiency for providers, payers, and patients.Real-time intelligence opens the door for more effective value-based care arrangements. When providers can see financial implications instantly, incentives align more naturally.The long-term vision includes real-time payment flows, AI-driven clinical decision support, and improved patient engagement. Breaking down paper-based silos will unlock entirely new use cases at scale.Resources:Connect with and follow Madhu Pawar on LinkedIn.Follow Optum on LinkedIn and visit their website.

In this episode, host Sandy Vance sits down with Hadas Bitran, Partner General Manager of Health AI at Microsoft Health & Life Sciences, for a deep dive into the rapidly evolving world of healthcare agents. Together, they explore how agentic technologies are being used across clinical settings, where they’re creating value, and why tailoring these tools to the specific needs of users and audiences is essential for safety and effectiveness. Well-designed healthcare agents can reinforce responsible AI practices (like transparency, accountability, and patient safety) while also helping organizations evaluate emerging solutions with greater clarity and confidence. In this episode, they talk about:How agents are used in healthcare and use casesThe risks if a healthcare agent is not tailored to the needs of users and audiencesHow healthcare agents support responsible AI practices, such as safety, transparency, and accountability, in clinical settingsHealthcare organizations should look to evaluate healthcare agent solutionsBridging the gaps in access, equity, and health literacy; empowering underserved populations and democratizing expertiseThe impact of AI on medical professionals and the healthcare staff, and how they should prepare for the change?A Little About Hadas:Hadas Bitran is Partner General Manager, Health AI, at Microsoft Health & Life Sciences. Hadas and her multi-disciplinary R&D organization build AI technologies for health & life sciences, focusing on Generative AI-based services, Agentic AI, and healthcare-adapted safeguards. They shipped multiple products and cloud services for the healthcare industry, which were adopted by thousands of customers worldwide.In addition to her work at Microsoft, Hadas previously served as a Board Member at SNOMED International, a not-for-profit organization that drives clinical terminology worldwide.Before Microsoft, Hadas held senior leadership positions managing R&D and Product groups in tech corporations and in start-up companies. Hadas has a B.Sc. in Computer Science from Tel Aviv University and an MBA from the Kellogg School of Management, Northwestern University in Chicago.

About Mary Varghese Presti:Mary Varghese Presti is a transformational healthcare leader with over two decades of experience spanning clinical care, federal reform, biopharma, and health technology. As Corporate Vice President of Microsoft Health & Life Sciences, she drives growth in complex environments by creating clear strategy, aligning organizations, and operationalizing execution with discipline. Her prior roles include leading Nuance’s Dragon Medical business, overseeing IBM Watson Health’s Life Sciences portfolio, incubating new ventures at athenahealth, and driving digital-health transformation at Pfizer. She began her career as a pediatric nurse at Johns Hopkins and later helped shape national health IT and payment reforms at Booz Allen. Known for navigating complexity with optimism and rigor, she consistently turns ambiguity into strategy and strategy into measurable results.Things You’ll Learn:AI in healthcare is evolving from simple assistants to agentic services that can independently execute predictable workflows, allowing clinicians to regain time and focus. This shift enables a hybrid workforce where human and digital colleagues work side by side.Dragon Copilot for nurses was designed specifically to support the way nurses document care, capturing structured inputs such as vitals, intake/output, and observations through natural speech. By reducing EHR time and ambiently recording bedside interactions, it helps turn “caring out loud” into complete documentation.Nurses spend more than a quarter of their 12-hour shifts documenting in the EHR, often feeling emotionally torn between screens and patients. AI that listens in the background can significantly reduce this burden while allowing for more presence at the bedside.New tools are starting to expose the “invisible work” nurses perform, from constant micro-assessments to coordination with ancillary departments. Making this work visible is a critical step toward properly valuing nursing labor and improving workforce planning.Real-world use cases, such as AI agents assembling data for tumor boards at academic centers, show that agentic workflows can compress decision timelines from weeks to days. These same principles can be extended to many clinical and non-clinical tasks, accelerating care while preserving clinician judgment.Resources:Connect with and follow Mary Varghese Presti on LinkedIn.Follow Microsoft on LinkedIn.Visit the Microsoft and Life Sciences website.Listen to Mary’s previous interview on our podcast here.Watch Mary’s keynote presentation at the HLTH conference here.

About Heather Grey:Heather Grey is a healthcare operator and commercial leader who has spent two decades inside the machinery of pharma, life sciences, and clinical research—seeing firsthand where trials break down and why execution matters more than ideas. As SVP and General Manager of Real-World Data and Clinical Trials at Omega Healthcare, she leads CurateIQ, which focuses on transforming messy, fragmented clinical data into FDA-grade assets that accelerate trials, support AI, and expand research beyond academic centers. Before Omega, she held senior leadership roles at Tempus AI, where she built and scaled clinical trial and RWD commercial operations, and at Optum Life Sciences, driving sales and client development across pharma and health systems. Her career spans everything from operating room work to frontline pharma sales to executive leadership, giving her a rare, end-to-end view of how science, data, and operations collide in the real world, and why clean data and operational discipline, not hype, determine whether innovation actually reaches patients.Things You’ll Learn: Clinical trials fail primarily due to operational breakdowns, such as delayed data entry, poor site readiness, and missed timelines, rather than flawed science.Most healthcare data exists in an unstructured and unusable state, making human-led curation essential for generating regulatory-grade insights and training AI.AI should amplify clinical expertise, not replace it, because accuracy and trust depend on continuous human quality assurance.The lack of infrastructure prevents 88% of health systems and most community centers from offering clinical trials.Expanding trials into community settings is crucial for enhancing access, diversity, and the real-world relevance of research.Resources:Connect with and follow Heather Grey on LinkedIn.Follow Omega Healthcare on LinkedIn and visit their website.Email Heather directly here.

About James York:James York serves as the Chief Commercial Officer and Head of Government Affairs at Molecular Testing Labs, where he leads the company’s mission to expand access to diagnostics and transform patient engagement with their health. With over a decade of leadership experience at the organization, James drives commercial strategy, strategic partnerships, business development, and market education, championing a consumer-centric approach to laboratory medicine. His work focuses on advancing transparency, affordability, and proactive health management by ensuring that individuals, regardless of their circumstances or geography, can benefit from timely diagnostic insights. James’ career spans executive roles across healthcare, including CEO and president positions, as well as senior leadership in sales and business development, providing him with a deep understanding of both clinical and commercial landscapes. Guided by a commitment to equitable access and meaningful innovation, he continues to influence how advanced diagnostics are delivered and adopted across the healthcare ecosystem.Things You’ll Learn:Making diagnostics accessible requires removing economic, geographic, and emotional friction so patients can participate in their own care. At-home self-collection solves barriers that traditional labs cannot.Affordability is inseparable from access, and transparent low-cost testing is critical for supporting large populations who are “functionally uninsured.” Most patients avoid care because they cannot predict the financial burden.Virtual care has accelerated the need for decentralized diagnostics, as patients who seek care online are unlikely to travel to a physical laboratory. Without accessible testing, virtual clinical pathways break.Pioneering new diagnostic models is challenging, costly, and often met with resistance from incumbents and regulators. Yet these challenges highlight the significance of the innovation.The greatest opportunity in diagnostics lies not in high-tech breakthroughs but in improving everyday tests that influence most clinical decisions. Access, not technology, is the true innovation.Resources:Connect with and follow James York on LinkedIn.Follow Molecular Testing Labs on LinkedIn and visit their website. 

About Beth McCombs:Elizabeth “Beth” McCombs is the executive vice president and chief technology officer of BD, where she leads the company’s global research and development organization. She oversees the full spectrum of innovation—from early-stage concept development to product launch—and ensures the continued advancement of BD’s existing portfolio. As a member of the BD Executive Leadership Team, she plays a central role in shaping the company’s long-term technology and growth strategy. Beth joined BD in 2019 as Senior Vice President of R&D for the BD Medical segment, co-leading portfolio strategy and major growth initiatives. Before joining BD, she spent over two decades at Johnson & Johnson, including serving as Vice President of R&D for Ethicon, the company’s surgical devices franchise. She holds both a B.S. and an M.S. in mechanical engineering from the Massachusetts Institute of Technology and an MBA from the Wharton School of the University of Pennsylvania.Things You’ll Learn:BD approaches innovation by deeply studying clinical workflows and ensuring new technologies solve meaningful, scalable problems. Real-world evidence and clinical validation are built into the process from the start.Connected medication management solutions can eliminate waste, prevent errors, and free up clinical resources. Tracking drugs from the central pharmacy to the bedside improves safety and system-level efficiency.Vascular access improvements achieved through product design and standardized training dramatically reduced cost, blood exposure, and catheter failure rates. This proves that outcomes hinge on combining the right device with the right practices.AI and machine-learning capabilities, such as predicting hypotension during cardiac surgery, aim to reduce complications, costs, and length of stay. These tools evolve by partnering with health systems to measure real-world impact.BD Incada represents a shift to cloud-based, interoperable, AI-enabled infrastructure that unifies data across entire health systems. This foundation accelerates the future of personalized care and integrated device ecosystems.Resources:Connect with and follow Beth McCombs on LinkedIn.Follow BD on LinkedIn  and visit their website.

About Priya Abani:Priya Abani is the CEO, president, and a board member at AliveCor, where she leads the company’s mission to advance patient-centric remote cardiac care using cutting-edge AI and machine learning. With over 20 years of experience driving innovation across global technology organizations, she has built and scaled high-performing teams, launched industry-shaping products, and forged strategic partnerships that accelerate growth. Her leadership has earned recognition across the health tech landscape, including being named one of The Healthcare Technology Report’s Top 50 Healthcare Technology CEOs of 2022. Priya also serves on the Board of Directors for Jacobs and the Board of Trustees for TIAA, extending her influence across various sectors and shaping the future of technology, healthcare, and infrastructure.Things You’ll Learn:AI-powered cardiac monitoring is enabling earlier detection of subtle abnormalities that patients and clinicians often miss, improving the likelihood of timely intervention. These tools empower patients to monitor their own health without waiting for episodic visits.Affordability is crucial for expanding access, enabling individuals in underserved regions to utilize medical-grade ECG technology at home. This reduces unnecessary hospital visits and helps bridge geographical care gaps.Portable devices and continuous monitoring shift cardiac care from reactive to proactive. Real-time data sharing creates a tighter feedback loop between patients and clinicians.New clinician-facing tools offer advanced diagnostics in a pocket-sized form, enabling high-quality cardiac assessments to be performed anywhere. This supports healthcare workers who lack access to full clinical equipment.AI models trained on massive ECG datasets are evolving from simple detection tools into comprehensive health companions for the whole person. They synthesize patterns, prompt actions, and help guide personalized preventive care.Resources:Connect with and follow Priya Abani on LinkedIn.Follow AliveCor on LinkedIn and visit their website. Learn more about Kardia 12L here.

About Web Golinkin:Web Golinkin is a seasoned healthcare executive, entrepreneur, and author with more than 35 years of leadership experience, including six CEO roles and three companies he co-founded. Over the last two decades, he has focused on expanding access to affordable, basic healthcare, establishing himself as a pioneer in both retail-based clinics and urgent care. His insights into the evolution of consumer-focused healthcare have been featured in The Wall Street Journal, Forbes, The Today Show, Fox Business, and numerous industry conferences. Web is also the author of Here Be Dragons, published by Forbes Books in 2024. His career spans leadership positions across healthcare delivery, population health management, medical communications, and consumer health media, including his current role as president of Babson Diagnostics and previous leadership at FastMed Urgent Care, Health Dialog, RediClinic, America’s Health Network, and American Medical Communications. A graduate of Harvard University, Web continues to shape the future of healthcare through innovation, accessibility, and patient-centered design.Things You’ll Learn:Better Way can deliver 67 clinically equivalent tests from a fingertip blood sample, covering more than 80% of common primary care needs. This allows patients to avoid the traditional needle-based blood draw.Nearly a decade of validation, including thousands of study participants and hundreds of thousands of tests, demonstrates the scientific rigor behind the technology. This long research runway enabled FDA clearance and strong clinical confidence.About one-third of patients avoid blood testing due to needle phobia or inconvenience, contributing to major gaps in preventive care. A more straightforward, painless collection method directly addresses this barrier.Health systems can increase patient adherence and reduce reliance on phlebotomists by cross-training staff to use the system within 2.5 hours. This unlocks staffing flexibility and operational efficiency.Better Way focuses on reducing friction across the entire testing journey, including simplified, graphic-rich patient result reports. This empowers patients to understand their health without having to decipher complex medical language.Resources:Connect with and follow Web Golinkin on LinkedIn.Follow Babson Diagnostics on LinkedIn  and visit their website.

In this episode, host Sandy Vance sits down with someone who has been shaping the future of digital health long before AI became the headline Mike Serbinis, Founder and CEO of League.League was built on a simple but ambitious idea: if companies like Netflix can instantly understand what we need next, why can’t healthcare do the same? Now, more than a decade into transforming the way people access and experience care, Mike joins Sandy to talk about how his team is helping organizations deliver truly personalized healthcare at scale.Together, they explore Mike’s path into the world of AI, the early sparks that led to League’s creation, and the lessons learned from 11 years of reimagining patient and member journeys. They delve into how League works alongside existing EHRs and health systems, not replacing anything, but weaving intelligence and interoperability through the cracks that slow down care.It’s a thoughtful, future-forward discussion with one of the industry’s most seasoned innovators—and a must-listen for anyone curious about where healthcare AI is truly headed.In this episode, they talk about:Mike’s journey into AI and the origin story of LeagueHow League integrates with EHRs and other core health technologiesLessons from 11 years in healthcare—and why speed and scale matter more than everIf Netflix can recommend your next show, why can’t healthcare do the sameReducing AI hallucinations and improving reliability for healthcare organizationsHow League delivers coverage, oversight, service, and increased productivityWhat different countries can teach us about healthcare modelsWhy we’re entering “pilot season” for AI in healthcareA Little About Mike:Mike Serbinis is widely recognized as an innovative leader and serial entrepreneur who has built transformative technology platforms across many industries. Serbinis founded and helped build Kobo, Critical Path, DocSpace, and now League. Founded in 2014, League is a platform technology company powering next-generation healthcare consumer experiences (CX). Payers, providers and consumer health partners build on the League platform to accelerate their digital transformation and deliver high-engagement, personalized healthcare experiences. Millions of people use and love solutions powered by League to access, navigate and pay for care.Serbinis is also Chair of the Board of Directors for the Perimeter Institute for Theoretical Physics, the world’s leading center for scientific research in foundational theoretical physics. He is a founding board member of the Vector Institute for Artificial Intelligence, an institution co-founded by Nobel Prize winner Geoffrey Hinton.

About Seth Cohen:Seth Cohen is a seasoned business leader with a long record of driving growth across healthcare, technology, and finance. As president of Cedar, he leads strategy and execution for a fast-scaling health tech company, building on over a decade of leadership in the industry. He also serves on the boards of Firefly Health and previously served on the board of Castlight Health, reflecting his deep credibility in the healthcare ecosystem. Before joining Cedar, Seth co-founded OODA Health and served as its CEO, introducing innovative payment solutions to the market. His earlier career includes senior commercial roles at Castlight, where he helped large employers adopt modern health benefits, as well as consulting work at McKinsey, focused on healthcare reform and consumerism. Seth began his career in investment banking, private equity, and international development, providing him with a broad strategic and financial foundation. He holds an MBA from Harvard Business School, an MPA from Harvard Kennedy School, and a BA from Stanford University.Things You’ll Learn:Patient out-of-pocket costs have been rising faster than the overall medical trend for two decades, pushing most Americans into high-deductible plans they cannot realistically afford.A relatively small percentage of uninsured patients, roughly 5–12% depending on the state, accounts for approximately 35% of the dollars owed to providers. The episode challenges providers to rethink the concept of “healing” by asking whether repairing someone’s heart while ruining their credit can truly be considered care.Cedar Cover is positioned as a proactive digital coverage safety net that identifies patients in need and connects them to Medicaid, ACA plans, financial assistance, and pharmacy copay programs. Looking ahead, the guest expects affordability pressures to intensify and plans to expand into areas such as workers' compensation and Social Security benefits. The goal is to ensure that patients are not forced to choose between groceries and medical bills by making financial support an integral part of the core care experience.Resources:Connect with and follow Seth Cohen on LinkedIn.Follow Cedar on LinkedIn and discover their website.Learn more about Cedar Cover here.Email Seth directly here.

In this episode, host Sandy Vance sits with Adam Siskind from ZS, a global consulting and technology firm known for transforming data, science, and human ingenuity into real-world impact. With more than 13,000 employees across 35+ offices, ZS partners with companies to improve life and how we live it. Sandy and Adam dive into how AI and advanced analytics are reshaping operations, the insights coming out of ZS’s Future of Health Report, and what it will take to overcome lingering distrust in AI across healthcare. From predictions and concerns to practical advice for payers and providers, they explore whether we’re headed toward a tipping point or an AI bubble.In this episode, they talk about:How AI is facilitating solutions for ZSHow ZS uses analytics to drive how businesses operateZS’s Future of Health ReportGetting past the distrust in AI in healthcareWhat a tipping point might look like in the futureAdvice for payers and providersFuture implementation predictions and worriesIs there an AI bubble?A Little About Adam:Adam is a leader in ZS’s provider practice area, helping to transform hospitals and health systems and supporting them from strategy through to execution. He has extensive experience across healthcare with health plans, providers, pharmaceutical, biotech and medtech companies. Adam has also led ZS’s European and North America West regions. Adam’s background is in actuarial science. Before joining ZS, Adam worked with health plans and group insurance at Mercer, helping employer groups achieve high-quality and affordable healthcare.

About Lynne Nowak:Lynne Nowak, MD, is a seasoned physician executive and Chief Data and Analytics Officer with deep expertise at the intersection of clinical care, data, and technology. With 15 years of frontline experience as a board-certified internist and a decade leading large-scale data, interoperability, and clinical strategy initiatives, she has built a career transforming how information improves healthcare quality, access, and cost. She has overseen major enterprise investments, driven compliance with national interoperability standards, led advanced analytics and product development teams, and guided provider-focused digital solutions across complex organizations. Known for her high-energy, collaborative leadership style, she is committed to fixing a fragmented healthcare system while empowering patients, providers, and payers through smarter, connected data.Things You’ll Learn:Interoperability between providers, payers, pharmacies, and patients is becoming a powerful driver of access and outcomes. When information flows cleanly, underserved communities benefit the most.AI is only valuable when applied to problems that require deeper analysis, not simple workflows. The real gains come from using AI to handle complex record reviews while leaving simpler tasks to traditional automation.First-fill abandonment affects 20–30% of prescriptions, and most systems fail to notice because no claim is generated. Having visibility into these “silent failures” allows clinicians and plans to intervene earlier.Electronic benefit verification replaces days of manual phone calls with instant eligibility checks for patient assistance programs. This significantly reduces friction for patients attempting to initiate therapy.Automating prior authorizations can cut decision times from days to under 30 seconds. That speed directly affects access, adherence, and overall patient health.Resources:Connect with and follow Lynne Nowak on LinkedIn.Follow Superscripts on LinkedIn and visit their website.

About Ajay Gannerkote:Ajay Gannerkote is a global healthcare leader with deep experience spanning life sciences, medical devices, and healthcare services. Now serving as president of Integrated DNA Technologies (IDT), a Danaher company, he oversees the organization’s growth and strategic direction from Redwood City, California. Before IDT, he led Siemens Healthineers’ global ultrasound business as president and head, steering a complex, vertically integrated operation across more than 30 countries. Under his leadership, the business moved from negative growth and margins to strong, sustainable performance, becoming an industry leader in AI-driven clinical technology. Prior to that, he served as Director at KKR Capstone, where he co-led healthcare operations, drove large-scale transformations for portfolio companies, and created significant enterprise value across services and medical device sectors. Ajay spent more than a decade at McKinsey & Company as a partner in the Global Medical Products practice, advising Fortune 500 companies on product development, commercialization, operations, growth strategy, and large-scale turnarounds. Earlier in his career, he held leadership roles at Federal-Mogul, Cambridge Technology Partners, and Infosys, building a foundation in operations, technology, and global business integration. He holds an MBA in Corporate Strategy and Marketing from the University of Michigan’s Ross School of Business and a bachelor’s degree in Electronics and Telecommunications Engineering from the University of Mysore.Things You’ll Learn:Genomic technologies, such as NGS and MRD, are enabling earlier cancer detection, sometimes years ahead of traditional diagnostic methods. This early visibility allows clinicians to intervene sooner and build more personalized treatment strategies.Precision medicine is rapidly maturing as high-quality genomic data becomes central to diagnosis, monitoring, and therapy planning. The next era of oncology will rely heavily on personalized, data-driven decisions.Collaboration across industry, researchers, and regulatory bodies is essential for breakthrough medical innovations. A recent case of a rare disease demonstrates how a coordinated effort can compress the journey from diagnosis to therapy into just a few months.Custom manufacturing and high-quality reagents are critical enablers of clinically reliable genomic insights. Tailored solutions allow researchers and clinicians to analyze tumor-specific markers with greater accuracy and confidence.Strong leadership in genomics requires trust, transparency, and a willingness to challenge assumptions. Ajay’s “obligation to dissent” principle encourages continuous innovation and pushes teams to think beyond the status quo.Resources:Connect with and follow Ajay Gannerkote on LinkedIn.Follow Integrated DNA Technologies on LinkedIn and visit their website.

About Dylan Papa:Dylan Papa is a seasoned healthcare technology executive with more than a decade of leadership experience at Zelis, where he has played a central role in driving commercial growth, transformation, and data-driven strategy. Now serving as Senior Vice President of Commercial Growth, he brings a strong track record of expanding revenue, shaping organizational direction, and guiding high-impact initiatives across the payments and cost-management ecosystem. Throughout his tenure, Dylan has held progressive leadership roles spanning growth and transformation, payments transformation, business insights and analytics, and business solutions—each one sharpening his expertise at the intersection of healthcare, technology, and financial operations. His career began in analytics and business development, giving him a grounded, operational understanding of the industry he now helps steer at a strategic level. Backed by a foundation in finance from Montclair State University, Dylan combines analytical rigor with a forward-looking mindset, making him a trusted leader in navigating complex healthcare challenges and scaling innovative solutions.Things You’ll Learn:Providers increasingly want secure, simple, and expedited transactions supported by actionable data. This shift gives them more control while improving payer efficiency.Modernizing payments isn’t just about speed; it's about giving providers a single, transparent view of all transactions across multiple payers. This visibility helps them reduce denials, identify payment discrepancies, and forecast revenue more accurately.Consumer expectations for transparency and personalized benefits are pushing healthcare toward more flexible, customized models. Younger generations especially demand clearer information and greater financial control.Fragmentation remains the biggest obstacle in modernizing healthcare payments, from legacy tech stacks to inconsistent treasury processes. Harmonizing these systems is essential for building a seamless, end-to-end experience.The next frontier is transforming payments from an administrative task into a strategic asset. When speed, transparency, and control converge, every stakeholder—payer, provider, and consumer—wins.Resources:Connect with and follow Dylan Papa on LinkedIn.Follow Zelis on LinkedIn and visit their Website.

Introduction: In this episode, host Sandy Vance sits down with Joerg Schwarz, Senior Director of Industry Strategy & Solutions for Healthcare Interoperability at Infor, and Adam Luff, a healthcare technology executive and VP of Solution Consulting at Infor. Together, they take a fascinating look at the real-world state of healthcare data. Together, they unpack what AI is actually doing for the industry, why pulling meaningful information from existing systems is so challenging, and how proprietary schemas and non-queryable databases keep organizations stuck with costly “zombie systems.” They explore the promise of using AI to finally unlock that trapped data, along with the critical measures needed to ensure accuracy, quality, and transparency as new technologies evolve. Make sure to check out this episode if you’ve ever wondered what’s behind the “black box” of healthcare data.In this episode, they talk about:What AI does for the healthcare industryThe challenges that come with extracting dataWhy the data in current databases isn’t searchable and queryableProprietary schemas Unable to pull one data table at a timeUsing AI to extract data from zombie systems The time and money it takes to keep zombie systems aliveMeasures with new tech that need to be taken to ensure accuracy and qualityTransparency and rejecting the “black box” approachA Little About Joerg and Adam:As a trusted and highly skilled Global Business Strategy Executive and seasoned thought leader in the Healthcare IT domain, Joerg keeps an acute focus on the customer while leading teams, building strategic partnerships, and delivering solutions with measurable outcome improvements. His knowledge runs wide and deep with a 360-degree vantage point through the lenses of Technology, Sales, Marketing, and Academia. He combines the realities of leading key stakeholders and teams through innovation with respect to Healthcare IT and Life Sciences throughout his distinguished career. Joerg is highly motivated towards the evolution of connected managed care, population health, and clinical analytics. Communicating complexity is a signature quality Joerg possesses in service to delivering mutual benefit "win-win-win’s" by successfully navigating complex problems, accelerating brand and product growth, and being a key contributor in go-to-market decisions.Adam Luff is a healthcare technology executive and VP of Solution Consulting at Infor. With his 25 years in the Healthcare Technology industry, Adam focuses on operational efficiency that leads to providers getting paid faster and simpler.

About Liana Guzmán:Liana M. Douillet Guzmán is a seasoned CEO and consumer-tech leader known for driving transformative growth across healthcare, finance, education, and professional services. As CEO of FOLX Health, she has expanded the company’s national reach and service offerings, helping establish it as the leading digital healthcare provider for the LGBTQIA+ community. With nearly two decades of experience scaling disruptive companies, she previously served as CMO at Skillshare and COO at Blockchain, where she played a key role in growing the platform from 4 million to 40 million users and building a globally recognized brand. Liana also spent nine years shaping Axiom’s international expansion and marketing strategy across the U.S., EMEA, and APAC regions. A Henry Crown Fellow and three-time Fast Company Queer 50 honoree, she is a sought-after speaker at global forums including DAVOS, Fortune Brainstorm, Web Summit, and HLTH. Beyond her executive work, she co-founded The Pink Agenda and serves on the boards of GLAAD and The Elizabeth Park Conservancy. Born and raised in Puerto Rico, she brings a global mindset and people-first leadership style to every role.Things You’ll Learn:Whole-person, patient-centered, community-oriented care is the future. When these three pillars align, outcomes improve and trust increases across populations.Telehealth is not a compromise; it’s often the safest, most accessible option. For many people, digital care is the only environment where they feel safe, respected, and willing to seek support.AI can either transform healthcare or exacerbate and dangerously amplify inequality. Without careful oversight and representative data, large language models can reinforce harmful misinformation.Affirming care is a clinical and financial necessity, not a niche service. Avoiding preventive care can lead to dangerous delays and significantly higher system costs.Demographic shifts make inclusive care a strategic imperative. With a quarter of Gen Z identifying as LGBTQIA+, employers and payers who invest early will capture long-term loyalty and economic value.Resources:Connect with and follow Liana Guzmán on LinkedIn.Follow FOLX Health on LinkedIn and Instagram, and visit their website. 

About Ben Forrest:Ben Forrest is the CEO of Olio, a care coordination technology company focused on improving collaboration among payers, health systems, and post-acute providers for the most complex patients. With a 14-year background in the medical device industry, Ben saw firsthand how fragmented workflows and siloed care settings created barriers to quality and efficiency—an insight that led him to build Olio. Under his leadership, the platform now enables real-time engagement across hundreds of care sites, helping organizations reduce administrative burden, improve outcomes, and better manage medical spend. Ben is dedicated to bringing modern software, thoughtful workflows, and emerging AI capabilities to one of healthcare’s most persistent challenges: truly connected care.Things You’ll Learn:Care coordination is deeply fragmented, especially for complex patients moving across hospitals, skilled nursing, home health, behavioral health, and other community settings.Olio’s platform connects payers, health systems, and post-acute providers in one shared workflow, enabling daily engagement and reducing administrative burden.Better downstream provider engagement directly improves outcomes and lowers costs, especially in Medicare Advantage, Medicaid, ACO, and bundled payment environments.Scaling coordination statewide requires more than EMRs; it requires workflow technology that ensures transparency, accountability, and consistent communication across 100+ care sites.Economics drive engagement: care coordination intensity increases where organizations hold risk or face pressure to manage total medical spend.The future of AI in care coordination is still emerging, and smart companies will focus on doing one operational problem exceptionally well before expanding.Payers will face mounting pressure to reduce medical spend, making true care coordination, not just better authorization practices, a strategic necessity.Olio was born from the realization that healthcare excels at delivering care in silos but struggles when patients move between settings, especially under value-based models.Resources:Connect with and follow Ben Forrest on LinkedIn.Follow Olio on LinkedIn and discover their website. 

About Trudy McKanna:Trudy McKanna is an accomplished medical affairs leader with extensive experience across medical education, field medical strategy, and people management. Currently serving as Senior Field Medical Director at GRAIL, she brings more than two decades of expertise spanning oncology, organ health, genetics, and medical ethics. Prior to GRAIL, she spent nine years at Natera in progressively senior roles, including Senior Director of Medical Affairs for Organ Health, where she led medical strategy, built and managed high-performing teams, and shaped national KOL engagement efforts across transplant and renal genetics. Her background includes over a decade as a genetic counselor and supervisor at Spectrum Health, leadership roles in professional organizations such as the Michigan Association of Genetic Counselors, and academic appointments with Michigan State University. As co-founder and vice president of the Rockford Food Allergy Network, she also helped strengthen community education and advocacy around food allergy awareness. Trudy holds a Master of Science in Genetic Counseling from the University of Michigan and a Bachelor of Science in Biology/Biochemistry from Hope College.Things You’ll Learn:Early detection significantly changes survival outcomes; identifying cancer before it metastasizes can quadruple five-year survival rates.Multi-cancer early detection utilizes cell-free DNA and methylation patterns to detect signals from over 50 cancers with a simple blood draw.Adding this test to standard screening results in seven times more cancers being found, with over half detected at early stages.The false-positive rate is exceptionally low at 0.4%, making it viable for population-scale screening.Access and equity improve significantly when screening can be conducted in primary care settings, mobile units, employer sites, and underserved communities.Resources:Connect with and follow Trudy McKanna on LinkedIn.Follow GRAIL on LinkedIn and visit their website.Learn more about Galleri here.